Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05033990 | RECRUITING | COPD, Early-Onset

SPIROMICS Study of Early COPD Progression (SOURCE)
Sponsor:

University of Massachusetts, Worcester

Information provided by (Responsible Party):

Fernando Martinez

Brief Summary:

This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers predictive of smokers that will develop COPD. * To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related questionnaires assessing medical history, smoke exposure and use, medication use, social and behavioral health, pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine samples, pulmonary function testing to determine function, sputum induction to provide a sputum sample for airway biospecimen analysis, and CT imaging of the lungs.

Condition or disease

COPD, Early-Onset

Study Type : OBSERVATIONAL
Estimated Enrollment : 1000 participants
Official Title : SPIROMICS Study of Early COPD Progression (SOURCE)
Actual Study Start Date : 2021-09-08
Estimated Primary Completion Date : 2026-04
Estimated Study Completion Date : 2026-04

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 30 Years to 55 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * 40 of the 1000 will be healthy controls: ages 30-55 years; with no smoking history (\< 100 cigarettes in lifetime), including vaping and cannabis use; pre-bronchodilator FEV1/FVC \> 0.70; pre-bronchodilator FEV1 \> 80% predicted; pre-bronchodilator FVC \> 80% predicted; Chronic Airway Assessment Test (CAAT) score \< 10. Willingness to also participate in the bronchoscopy sub-study is only required of the 20 healthy controls recruited from the clinical centers participating in the sub-study.
  • * Approximately one-third of the 960 will be GOLD 0 participants: ages 30-55 years; with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \> 0.70 and FEV1 \> 80% predicted.
  • * Approximately one-third of the 960 will be Preserved Ratio Impaired Spirometry (PRISm) participants: ages 30-55 years; with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \> 0.70 and FEV1 \< 80% predicted.
  • * Approximately one-third of the 960 will be GOLD 1-2 participants: ages 30-55 years; with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 \> 50% predicted.
Exclusion Criteria
  • * Severe asthma, which is defined as any of the following
    • * Current (i.e., at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroids (ICS)/long-acting beta agonist (LABA) or high dose ICS or add-on long-acting muscarinic agonist (LAMA); Medium dose \> 250 fluticasone propionate, = 100 fluticasone furoate, \> 200 beclomethasone, \> 400 budesonide, \> 220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS; or
    • * Three or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months; or
    • * One asthma hospitalization in the past 12 months.
    • * Concurrent participation in a therapeutic trial where treatment is blinded.
    • * Active pregnancy at the time of the baseline visit or planning to become pregnant during the course of the study. This special population is being excluded to minimize potential for fetal radiation exposure.
    • * Cognitive dysfunction that prevents the participant from completing study procedures.
    • * BMI \> 35.0 kg/m\^2 at baseline, due to the effects of body weight on CT scan imaging quality.
    • * The presence of a respiratory condition other than COPD (including chronic bronchitis and emphysema) or asthma, such as interstitial lung disease or pulmonary fibrosis, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g., dyspnea or decreased exercise tolerance).
    • * Any illness expected to cause mortality in the next three years.
    • * Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan image quality.
    • * History of thoracic radiation or thoracic surgery with resection of lung tissue.
    • * Known HIV/AIDS infection.
    • * Current illicit substance abuse, excluding marijuana.
    • * History of or current use of IV Ritalin.
    • * History of or current use of heroin.
    • * History of illegal IV drug use within the last 10 years or more than 5 instances of illegal IV drug use ever.
SPIROMICS Study of Early COPD Progression (SOURCE)

Location Details

NCT05033990

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, alabama

University of Alabama at Birmingham

Birmingham, alabama, United States, 35205

RECRUITING

United States, Arizona

Mayo Clinic Arizona

Scottsdale, Arizona, United States, 85259

RECRUITING

United States, California

University of California Los Angeles

Los Angeles, California, United States, 90095

RECRUITING

United States, California

University of California, San Francisco

San Francisco, California, United States, 94143

RECRUITING

United States, Colorado

National Jewish Health

Denver, Colorado, United States, 80206

RECRUITING

United States, Illinois

University of Illinois Chicago

Chicago, Illinois, United States, 60608

RECRUITING

United States, Iowa

University of Iowa

Iowa City, Iowa, United States, 52242

RECRUITING

United States, Maryland

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States, 21224

RECRUITING

United States, road cancer

University of Michigan

Ann Arbor, road cancer, United States, 48130

RECRUITING

United States, New York

Columbia University

New York, New York, United States, 10032

RECRUITING

United States, New York

Weill Cornell Medical Center

New York, New York, United States, 10065

RECRUITING

United States, North Carolina

Wake Forest

Winston-Salem, North Carolina, United States, 27104

RECRUITING

United States, Pennsylvania

Temple University

Philadelphia, Pennsylvania, United States, 10140

RECRUITING

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84108